318 related articles for article (PubMed ID: 16440400)
21. Platinum metallodrug-protein binding studies by capillary electrophoresis-inductively coupled plasma-mass spectrometry: characterization of interactions between Pt(II) complexes and human serum albumin.
Timerbaev AR; Aleksenko SS; Polec-Pawlak K; Ruzik R; Semenova O; Hartinger CG; Oszwaldowski S; Galanski M; Jarosz M; Keppler BK
Electrophoresis; 2004 Jul; 25(13):1988-1995. PubMed ID: 15237398
[TBL] [Abstract][Full Text] [Related]
22. Biodistribution of the novel anticancer drug sodium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] KP-1339/IT139 in nude BALB/c mice and implications on its mode of action.
Bytzek AK; Koellensperger G; Keppler BK; G Hartinger C
J Inorg Biochem; 2016 Jul; 160():250-5. PubMed ID: 26993078
[TBL] [Abstract][Full Text] [Related]
23. Combination of ICP-MS, capillary electrophoresis, and their hyphenation for probing Ru(III) metallodrug-DNA interactions.
Foteeva LS; Matczuk M; Pawlak K; Aleksenko SS; Nosenko SV; Karandashev VK; Jarosz M; Timerbaev AR
Anal Bioanal Chem; 2017 Mar; 409(9):2421-2427. PubMed ID: 28116493
[TBL] [Abstract][Full Text] [Related]
24. Advances of CE-ICP-MS in speciation analysis related to metalloproteomics of anticancer drugs.
Timerbaev AR; Pawlak K; Aleksenko SS; Foteeva LS; Matczuk M; Jarosz M
Talanta; 2012 Dec; 102():164-70. PubMed ID: 23182589
[TBL] [Abstract][Full Text] [Related]
25. A comparative study of adduct formation between the anticancer ruthenium(III) compound HInd trans-[RuCl4(Ind)2] and serum proteins.
Piccioli F; Sabatini S; Messori L; Orioli P; Hartinger ChG; Keppler BK
J Inorg Biochem; 2004 Jun; 98(6):1135-42. PubMed ID: 15149825
[TBL] [Abstract][Full Text] [Related]
26. Toward high-throughput monitoring of metallodrug-protein interaction using capillary electrophoresis in chemically modified capillaries.
Shmykov AY; Filippov VN; Foteeva LS; Keppler BK; Timerbaev AR
Anal Biochem; 2008 Aug; 379(2):216-8. PubMed ID: 18498756
[TBL] [Abstract][Full Text] [Related]
27. Interactions of a novel ruthenium-based anticancer drug (KP1019 or FFC14a) with serum proteins--significance for the patient.
Hartinger CG; Hann S; Koellensperger G; Sulyok M; Groessl M; Timerbaev AR; Rudnev AV; Stingeder G; Keppler BK
Int J Clin Pharmacol Ther; 2005 Dec; 43(12):583-5. PubMed ID: 16372526
[No Abstract] [Full Text] [Related]
28. LC- and CZE-ICP-MS approaches for the in vivo analysis of the anticancer drug candidate sodium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] (KP1339) in mouse plasma.
Bytzek AK; Boeck K; Hermann G; Hann S; Keppler BK; Hartinger CG; Koellensperger G
Metallomics; 2011 Oct; 3(10):1049-55. PubMed ID: 21935553
[TBL] [Abstract][Full Text] [Related]
29. Characterization of interactions between organotin compounds and human serum albumin by capillary electrophoresis coupled with inductively coupled plasma mass spectrometry.
Sun J; He B; Liu Q; Ruan T; Jiang G
Talanta; 2012 May; 93():239-44. PubMed ID: 22483905
[TBL] [Abstract][Full Text] [Related]
30. Metallomics for drug development: a further insight into intracellular activation chemistry of a ruthenium(III)-based anticancer drug gained using a multidimensional analytical approach.
Matczuk M; Prządka M; Aleksenko SS; Czarnocki Z; Pawlak K; Timerbaev AR; Jarosz M
Metallomics; 2014 Jan; 6(1):147-53. PubMed ID: 24247321
[TBL] [Abstract][Full Text] [Related]
31. Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339.
Heffeter P; Böck K; Atil B; Reza Hoda MA; Körner W; Bartel C; Jungwirth U; Keppler BK; Micksche M; Berger W; Koellensperger G
J Biol Inorg Chem; 2010 Jun; 15(5):737-48. PubMed ID: 20221888
[TBL] [Abstract][Full Text] [Related]
32. The role of cisplatin and NAMI-A plasma-protein interactions in relation to combination therapy.
Khalaila I; Bergamo A; Bussy F; Sava G; Dyson PJ
Int J Oncol; 2006 Jul; 29(1):261-8. PubMed ID: 16773208
[TBL] [Abstract][Full Text] [Related]
33. Influence of ascorbic acid on the activity of the investigational anticancer drug KP1019.
Bartel C; Egger AE; Jakupec MA; Heffeter P; Galanski MS; Berger W; Keppler BK
J Biol Inorg Chem; 2011 Dec; 16(8):1205-15. PubMed ID: 21706338
[TBL] [Abstract][Full Text] [Related]
34. EPR as a probe of the intracellular speciation of ruthenium(III) anticancer compounds.
Webb MI; Walsby CJ
Metallomics; 2013 Dec; 5(12):1624-33. PubMed ID: 24057014
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation study.
Lentz F; Drescher A; Lindauer A; Henke M; Hilger RA; Hartinger CG; Scheulen ME; Dittrich C; Keppler BK; Jaehde U;
Anticancer Drugs; 2009 Feb; 20(2):97-103. PubMed ID: 19209025
[TBL] [Abstract][Full Text] [Related]
36. Drug-human serum albumin binding studied by capillary electrophoresis with electrochemiluminescence detection.
Zhao X; You T; Liu J; Sun X; Yan J; Yang X; Wang E
Electrophoresis; 2004 Oct; 25(20):3422-6. PubMed ID: 15490448
[TBL] [Abstract][Full Text] [Related]
37. Increasing the bioavailability of Ru(III) anticancer complexes through hydrophobic albumin interactions.
Webb MI; Wu B; Jang T; Chard RA; Wong EW; Wong MQ; Yapp DT; Walsby CJ
Chemistry; 2013 Dec; 19(50):17031-42. PubMed ID: 24203647
[TBL] [Abstract][Full Text] [Related]
38. Anticancer ruthenium(III) complex KP1019 interferes with ATP-dependent Ca2+ translocation by sarco-endoplasmic reticulum Ca2+-ATPase (SERCA).
Sadafi FZ; Massai L; Bartolommei G; Moncelli MR; Messori L; Tadini-Buoninsegni F
ChemMedChem; 2014 Aug; 9(8):1660-4. PubMed ID: 24920093
[TBL] [Abstract][Full Text] [Related]
39. Recent developments in ruthenium anticancer drugs.
Levina A; Mitra A; Lay PA
Metallomics; 2009 Nov; 1(6):458-70. PubMed ID: 21305154
[TBL] [Abstract][Full Text] [Related]
40. Binding Kinetics of Ruthenium Pyrithione Chemotherapeutic Candidates to Human Serum Proteins Studied by HPLC-ICP-MS.
Marković K; Milačič R; Marković S; Kladnik J; Turel I; Ščančar J
Molecules; 2020 Mar; 25(7):. PubMed ID: 32225069
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
